CA
NZ
UK
AU
IND
US
The move was sharp, but the uploaded reference notes that no clear company-specific catalyst was identified for the day. Instead, the rally appears consistent with a technical rebound after the stock had recently entered oversold territory, with its RSI falling below 30 in early …
The rally followed the company’s presentation at the Goldman Sachs 47th Annual Global Healthcare Conference, where management highlighted stronger operating momentum and raised its 2026 outlook. The uploaded reference notes that Alignment now expects 2026 revenue of $5.16 billion to $5.21 billion and adjusted …
The catalyst was the company’s announcement that elraglusib, its lead drug candidate, was selected for evaluation in the BEACON2 clinical trial for relapsed and refractory high-risk pediatric neuroblastoma.
For an industry defined by the constant need to replenish pipelines, GSK's willingness to deploy such a large sum reflects both conviction and urgency. Market attention has turned to why GSK chose this moment and this target, and what the deal reveals about the …
Nuvalent, Inc. (NASDAQ:NUVL) surged 39.11% during the June 9 regular session, rising to $123.10 from a previous close of $88.49. The stock opened at $122.81 and traded between $122.80 and $123.62, withVolumeof about 46.75 million shares.
UnitedHealth Group Incorporated (NYSE: UNH) is the largest health-care company in the United States by revenue and a major component of the S&P 500, with a marketCapitalizationaround $363 billion in mid-2026. Through its health-insurance and health-services businesses, UnitedHealth touches the care of well over …
Merck & Co. Inc. (NYSE: MRK) is one of the largest pharmaceutical companies in the S&P 500, with a marketCapitalizationaround $298 billion in mid-2026. A global leader in prescription medicines and vaccines, Merck is best known for Keytruda, one of the world's top-selling cancer …
Tango Therapeutics is a company that has been making waves in the oncology sector with its innovative approach to cancer treatment. The company's recent announcement of a 92% response rate in pancreatic cancer treatment has sent shockwaves through the industry, with its stock surging …
The recent 11% rise in IDEAYA Biosciences’ stock price ahead of its $300 million equity offering exemplifies a notable market phenomenon: institutional investors appear to be endorsing the company's future prospects rather than recoiling in anticipation of dilution. Typically, equity offerings lead to a …
The recent 14% surge in Zevra Therapeutics' stock price reflects the market's enthusiastic response to the company’s filing for a new composition of matter patent for MIPLYFFA (arimoclomol). This FDA-approved treatment for Niemann-Pick disease type C (NPC) is now set to enjoy exclusivity until …
Please wait processing your request...